ZipLine Medical has secured approval from the China Food and Drug Administration (CFDA) for its for non-invasive Zip skin closure system.

Zip is an easy to use wound closure device, which replaces traditional sutures, staples and glue for surgical incisions and lacerations.

With its micro-adjustability and reversibility, the device offers surgeons with precise control and flexibility during closure.

The device will enable to avoid skin punctures compared against staples or sutures, helping to minimize added pathways for bacteria to enter.

ZipLine said the devices' benefits has been demonstrated in clinical studies in orthopedic total-joint arthroplasty, cardiothoracic surgery, electrophysiology and dermatology.

The company recently exhibited the device at the 11th International Congress of the Chinese Orthopaedic Association, held in Beijing.

ZipLine Medical president and CEO John Tighe said: “The non-invasive Zip closure is ideally suited for the healthcare market in China, in light of its large and growing procedure volume, need for cost-effective and efficient solutions, and appreciation of aesthetics.

“We look forward to working with our team of distribution partners across China to bring the speed, safety, comfort and convenience of Zip to Chinese patients.”

ZipLine is engaged in the development of non-invasive surgical skin closure devices. The firm;s devices are available in around 30 countries across the globe.